Cytokines

Philogen Announces R&D Program Update

Retrieved on: 
Friday, July 2, 2021
Branches of biology, Medical specialties, Clinical medicine, Cytokines, Immunology, Inflammatory cytokine, Clusters of differentiation, Cytokine, Tumor necrosis factor, Immunotherapy, E-selectin, L19

A full pipeline update will be made to the market on 28 September, 2021, in the Companys Half Year results announcement.

Key Points: 
  • A full pipeline update will be made to the market on 28 September, 2021, in the Companys Half Year results announcement.
  • Fibromun (L19TNF), wholly-owned by Philogen, is a fully-human immunomodulatory product consisting of the L19 antibody and TNF (a strong pro-inflammatory cytokine).
  • The results from these studies will provide the basis for a pivotal clinical program in selected cancer types.
  • Philogen accepts no responsibility for the data protection policy and customer information of websites of third parties and shall not be liable for the content or web pages of third parties which are linked to the Philogen website, or which display the Philogen website in frames.

Savara Announces First Patient Dosed in Pivotal Phase 3 Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Trial

Retrieved on: 
Wednesday, June 30, 2021
Biotechnology, Pharmaceutical, Health, Clinical trials, Cytokines, Branches of biology, Medical specialties, Organ systems, Autoimmune diseases, Pulmonary alveolar proteinosis, Granulocyte-macrophage colony-stimulating factor, Colony-stimulating factor, Savara

Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that the first patient has been dosed in the pivotal IMPALA-2 clinical trial.

Key Points: 
  • Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that the first patient has been dosed in the pivotal IMPALA-2 clinical trial.
  • IMPALA-2 is a Phase 3 trial designed to evaluate the efficacy and safety of molgramostim compared to placebo.
  • With the first patient dosed in IMPALA-2, we hit a critical milestone in-line with our guidance for the trial, said Badrul Chowdhury, M.D., Ph.D., Chief Medical Officer, Savara.
  • Our lead program, molgramostim nebulizer solution, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP).

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Athira Pharma, Inc. (ATHA)

Retrieved on: 
Tuesday, June 29, 2021
Legal, Professional services, Branches of biology, Cytokines, Hepatocyte growth factor

You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.

Key Points: 
  • You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.
  • Athira is a late-stage clinical biopharmaceutical company that is focused on developing small molecules to restore neuronal health and stop neurodegeneration.
  • These papers are foundational to Athiras efforts to treat Alzheimers because they established that a particular molecule affects the activity of HGF.
  • To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.

ATHIRA ALERT: Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against Athira Pharma, Inc. and Encourages Investors to Contact the Firm

Retrieved on: 
Tuesday, June 29, 2021
Legal, Professional services, Branches of biology, Cytokines, Hepatocyte growth factor, Lawsuit

Investors have until August 24, 2021 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

Key Points: 
  • Investors have until August 24, 2021 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
  • Athira is a late-stage clinical biopharmaceutical company that is focused on developing small molecules to restore neuronal health and stop neurodegeneration.
  • These papers are foundational to Athiras efforts to treat Alzheimers because they established that a particular molecule affects the activity of HGF.
  • The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country.

Connective Tissue Protein Fights Bacterial Infection while Restraining Dangerous Immune Overreaction in Sepsis

Retrieved on: 
Monday, June 28, 2021
Immunology, Branches of biology, Cytokines, Cytokine, Tumor necrosis factor, Septic shock

NEW YORK, June 28, 2021 /PRNewswire/ -- A connective tissue protein known to support the framework of organs also encourages immune responses that fight bacterial infections, while restraining responses that can be deadly in the condition called sepsis, a new study finds.

Key Points: 
  • NEW YORK, June 28, 2021 /PRNewswire/ -- A connective tissue protein known to support the framework of organs also encourages immune responses that fight bacterial infections, while restraining responses that can be deadly in the condition called sepsis, a new study finds.
  • Sepsis affects 48.9 million people worldwide, the authors say, but the role of the ECM in the condition is largely unknown.
  • This in turn leads to production of TNF alpha, a signaling protein that amplifies immune responses.
  • Experiments confirmed that mice engineered to lack the gene for lumican have trouble both fighting off bacterial infections (less cytokine response, slower clearance, greater weight loss), and trouble restraining the immune overreaction to bacteria (sepsis).

BetterLife Announces Exercise of Over-Allotment Option in Public Offering

Retrieved on: 
Friday, June 25, 2021
Financial economics, Options, Finance, Cytokines, Stock market, Equity securities, Contract law, Interferon, Warrant, Greenshoe, Money, Allotment

The total gross proceeds to the Company from the Offering, including the 6,525,000 Units sold initially and the partial exercise of the over-allotment option, is approximately $2,836,953.

Key Points: 
  • The total gross proceeds to the Company from the Offering, including the 6,525,000 Units sold initially and the partial exercise of the over-allotment option, is approximately $2,836,953.
  • Each Warrant entitles the holder thereof to purchase one Common Share at an exercise price of $0.50 expiring on May 28, 2024.
  • The net proceeds from the Offering will be used for working capital and general corporate purposes.
  • BetterLife is also refining and developing drug candidates from a broad set of complementary interferon-based technologies which have the potential to engage the immune system to fight virus infections.

New Study: Eating Prunes Daily Improves Risk Factors for Heart Disease and Inflammation in Postmenopausal Women

Retrieved on: 
Tuesday, June 22, 2021
Medical specialties, Branches of biology, Immunology, Cytokines, Clinical medicine, Cardiovascular disease, Inflammatory cytokine, Inflammation, Cytokine, Tumor necrosis factor, Oxygen radical absorbance capacity

ROSEVILLE, Calif., June 22, 2021 /PRNewswire/ --New research published in the Journal of Medicinal Food suggests eating prunes each day can improve risk factors for cardiovascular disease (CVD) including raising antioxidant capacity and reducing inflammation among healthy, postmenopausal women.

Key Points: 
  • ROSEVILLE, Calif., June 22, 2021 /PRNewswire/ --New research published in the Journal of Medicinal Food suggests eating prunes each day can improve risk factors for cardiovascular disease (CVD) including raising antioxidant capacity and reducing inflammation among healthy, postmenopausal women.
  • The research led by San Diego State University reveals that prunes can positively affect heart disease risk.
  • Eating prunes daily also promoted higher antioxidant capacity and lowered levels of the inflammatory cytokines interleukin-6 and tumor necrosis factor-alpha associated with CVD risk.
  • Notably, body mass index and weight of the study participants were maintained during the trial despite adding prunes to the usual diet.

BeyondSpring Announces First Quarter 2021 Financial Results and Provides a Corporate Update

Retrieved on: 
Wednesday, June 16, 2021
Branches of biology, Amgen, Cytokines, Granulocyte colony-stimulating factor, Food and Drug Administration, Priority review, Medical specialties, Medicine

June 2021: Announced Food and Drug Administration (FDA) filing of New Drug Application with Priority Review for plinabulin and G-CSF combination for the prevention of CIN.

Key Points: 
  • June 2021: Announced Food and Drug Administration (FDA) filing of New Drug Application with Priority Review for plinabulin and G-CSF combination for the prevention of CIN.
  • General and administrative (G&A) expenses were $6.4million for the quarter ended March 31, 2021, compared to $2.9million for the quarter ended March 31, 2020.
  • Net loss attributable to the Company was $17.0million for the quarter ended March 31, 2021, compared to $16.1million for the quarter ended March 31, 2020.
  • The management of BeyondSpring will host a conference call and webcast for the investment community today, June 16, 2021, at 8:30 am ET.

BeyondSpring Announces a Late-Breaking Poster Presentation of PROTECTIVE-2 Phase 3 Data Showing Plinabulin, in Combination with Pegfilgrastim, Reverses the Immune-Suppressive Effects of Pegfilgrastim and Offers Superior Prevention of Chemotherapy-Induced

Retrieved on: 
Tuesday, June 8, 2021
Branches of biology, Amgen, Growth factors, Recombinant proteins, Cytokines, Granulocyte colony-stimulating factor, Pegfilgrastim, Filgrastim, Plinabulin, Neutrophil, Myelocyte

Compared to pegfilgrastim alone (n=110), the plinabulin and pegfilgrastim combination (n=111) showed decreased production of immature neutrophil band (p=0.0012), and decreased promyelocytes and myelocyte production (p=0.0488).

Key Points: 
  • Compared to pegfilgrastim alone (n=110), the plinabulin and pegfilgrastim combination (n=111) showed decreased production of immature neutrophil band (p=0.0012), and decreased promyelocytes and myelocyte production (p=0.0488).
  • Immature neutrophil band and promyelocytes and myelocytes are less functional defending against infection and have potentially deleterious immune suppression effects.
  • The Company has submitted New Drug Applications (NDA) for plinabulin in combination with pegfilgrastim as a treatment for the prevention of CIN for review in both the U.S. and China.
  • Treatment or prevention of CIN with G-CSF has been the standard of care since Neupogen was approved in 1991.

Replimune Provides Data Update from its RP1 (vusolimogene oderparepvec) and RP2 Programs and Announces Plans to Expand the Development of RP2/3 Beyond Phase 1

Retrieved on: 
Thursday, June 3, 2021
Cytokines, Granulocyte-macrophage colony-stimulating factor, RP2

Additionally, Replimune announced plans to initiate a Phase 2 clinical trial program in tumor types that metastasize to the liver.

Key Points: 
  • Additionally, Replimune announced plans to initiate a Phase 2 clinical trial program in tumor types that metastasize to the liver.
  • As our data matures there are some clear themes emerging, said Philip Astley-Sparke CEO of Replimune.
  • RP2 leverages Replimunes platform to express an anti-CTLA-4 antibody, in addition to GALV-GP R- and GM-CSF expressed by RP1.
  • Whether RP2 or RP3 is used for particular tumor types will depend on the clinical data as it continues to emerge.